TrivarX Limited (MDBIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TrivarX Limited (MDBIF) trades at $0.00 with AI Score 45/100 (Grade C). TrivarX Limited (MDBIF) is a health technology company specializing in AI-driven diagnostic tools for behavioral health disorders. Market cap: $872,787, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for MDBIF: MDBIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MDBIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MDBIF: the 1 perspectives are evenly split.
How is this calculated? →TrivarX Limited (MDBIF) Healthcare & Pipeline Overview
TrivarX Limited (MDBIF) leverages advanced AI technology to develop innovative diagnostic instruments for behavioral health disorders, catering to both corporate health solutions and healthcare providers in Australia and the U.S.
What Is the Investment Thesis for MDBIF?
TrivarX Limited (MDBIF) is positioned to capitalize on the increasing demand for mental health solutions driven by rising awareness and acceptance of behavioral health disorders. The global mental health market is projected to grow significantly, providing a robust backdrop for TrivarX's innovative diagnostic tools and corporate health programs. Key value drivers include the company's focus on AI-driven solutions, which enhances diagnostic accuracy and efficiency, as well as its expansion into the U.S. market, where demand for mental health services is surging. The company's recent rebranding and strategic initiatives to broaden its product offerings will potentially increase its market share. However, investors should be mindful of the competitive landscape and regulatory challenges that could impact growth timelines.
Based on FMP financials and quantitative analysis
MDBIF Key Highlights
- Founded in 1987, TrivarX Limited has over three decades of experience in the healthcare technology sector.
- The company recently rebranded from Medibio Limited to TrivarX Limited in October 2023.
- TrivarX operates in both Australia and the United States, targeting a growing market for mental health solutions.
- The firm employs a small but dedicated team of six, focusing on innovation and product development.
- TrivarX offers AI-driven diagnostic tools and corporate mental well-being programs, addressing diverse market needs.
Who Are MDBIF's Competitors?
MDBIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDIBF Mediobanca Banca di Credito Finanziario S.p.A. | $28.96 | +0.00% | $23.36B | — |
| HCA HCA Healthcare, Inc. | $415.66 | +1.26% | $92.21B | 86 |
| MCK McKesson Corporation | $784.23 | -0.26% | $91.82B | 90 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDBIF's Key Strengths?
- Innovative AI-driven diagnostic tools tailored for behavioral health.
- Strong scientific validation enhances product credibility.
- Established presence in both Australian and U.S. markets.
- Dedicated team focused on continuous product development.
What Are MDBIF's Weaknesses?
- Limited workforce of six employees may restrict growth capacity.
- Dependence on a niche market could limit revenue diversification.
- Recent rebranding may require time to build brand recognition.
- Lack of established partnerships with major healthcare providers.
What Could Drive MDBIF Stock Higher?
- Expansion into the U.S. market with targeted marketing strategies.
- Development of new AI-driven diagnostic tools to enhance product offerings.
- Strategic partnerships with healthcare providers to increase market penetration.
- Continuous improvement of corporate mental well-being programs.
- Regulatory approvals for new products that may enhance marketability.
What Are the Key Risks for MDBIF?
- Financial-distress signal — its Altman Z-Score of -4.44 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-11.7%) — the business is not currently generating profit on shareholder capital.
- Regulatory challenges in obtaining necessary approvals for products.
- Intense competition from established healthcare technology firms.
- Economic downturns impacting corporate spending on health solutions.
- Rapid technological advancements leading to product obsolescence.
What Are the Growth Opportunities for MDBIF?
- Expansion into the U.S. Market: TrivarX Limited aims to penetrate the U.S. healthcare market, which is projected to grow significantly due to increased awareness and demand for mental health services. The U.S. mental health market is expected to reach USD 225 billion by 2030. By introducing its AI-driven diagnostic tools and corporate health programs, TrivarX can capture a share of this lucrative market, enhancing its revenue potential.
- Corporate Health Solutions: The demand for corporate mental well-being programs is on the rise as businesses increasingly recognize the importance of employee mental health. TrivarX's tailored programs can help organizations improve employee productivity and satisfaction. This segment is expected to grow at a CAGR of 5.2% over the next five years, providing TrivarX with an opportunity to expand its client base and revenue streams.
- AI-Driven Innovations: As technology continues to evolve, TrivarX's focus on AI-driven diagnostic tools positions it to lead in the healthcare technology space. The global AI in healthcare market is projected to reach USD 188 billion by 2030, growing at a CAGR of 37% from 2023. By continuously innovating and enhancing its product offerings, TrivarX can maintain a competitive edge and attract more clients.
- Partnerships with Healthcare Providers: Collaborating with healthcare providers can enhance TrivarX's visibility and market reach. By forming strategic partnerships, the company can integrate its diagnostic tools into existing healthcare systems, facilitating broader adoption. This approach can also lead to increased credibility and trust among potential clients, driving growth in sales and market share.
- Regulatory Approvals and Compliance: Successfully navigating regulatory approval processes for its products can open up new market opportunities for TrivarX. Gaining FDA or EMA approvals for its diagnostic tools can significantly enhance its marketability and enable entry into new regions. With a focus on compliance and quality, TrivarX can position itself as a trusted provider of mental health solutions.
What Opportunities Does MDBIF Have?
- Growing demand for mental health solutions in corporate settings.
- Expansion into the lucrative U.S. mental health market.
- Potential for strategic partnerships with healthcare organizations.
- Increasing awareness of mental health issues driving market growth.
What Threats Does MDBIF Face?
- Intense competition from established healthcare technology firms.
- Regulatory challenges in obtaining necessary approvals for products.
- Rapid technological advancements may lead to product obsolescence.
- Economic downturns could impact corporate spending on health solutions.
What Are MDBIF's Competitive Advantages?
- Strong focus on AI-driven technology, enhancing diagnostic accuracy.
- Established reputation for scientific validation of its products.
- Niche specialization in behavioral health diagnostics sets it apart from competitors.
- Expanding presence in both Australia and the U.S. markets, increasing brand recognition.
What Does MDBIF Do?
Founded in 1987, TrivarX Limited, previously known as Medibio Limited, is a pioneering health technology enterprise headquartered in Mount Lawley, Australia. The company specializes in creating advanced, AI-driven instruments designed for the detection and diagnosis of behavioral health disorders. Over the years, TrivarX has evolved its product offerings to include specialized mental well-being programs tailored for businesses, positioning itself as a comprehensive corporate health solution provider. The firm also develops various products aimed at the wider healthcare provider market, enhancing its reach and impact within the healthcare sector. In October 2023, the company rebranded to TrivarX Limited to better reflect its innovative approach and commitment to advancing mental health diagnostics. With a dedicated team of six employees, TrivarX is focused on expanding its footprint in both Australia and the United States, addressing the growing demand for effective mental health solutions and services. The company's commitment to scientific validation ensures that its products meet rigorous standards, making them reliable tools for healthcare professionals and corporate clients alike.
What Products and Services Does MDBIF Offer?
- Develop advanced AI-driven diagnostic tools for behavioral health disorders.
- Provide specialized mental well-being programs for businesses.
- Create products tailored for healthcare providers in the mental health sector.
- Focus on scientific validation to ensure the reliability of its instruments.
- Operate in both Australia and the United States, expanding its market reach.
- Engage in continuous innovation to enhance product offerings.
How Does MDBIF Make Money?
- Generate revenue through the sale of diagnostic tools and mental well-being programs.
- Offer corporate health solutions that cater to businesses seeking to improve employee mental health.
- Develop partnerships with healthcare providers to integrate products into their services.
- Leverage AI technology to enhance the efficiency and accuracy of diagnostic tools.
What Industry Does MDBIF Operate In?
The healthcare information services industry is experiencing rapid growth, fueled by increasing demand for mental health solutions and advancements in technology. The global mental health market is expected to reach USD 537 billion by 2030, reflecting a compound annual growth rate (CAGR) of 3.5% from 2023. TrivarX Limited is well-positioned within this landscape, offering innovative AI-driven diagnostic tools that cater to both healthcare providers and corporate clients. The competitive landscape includes various players focused on mental health solutions, but TrivarX's emphasis on scientifically validated instruments sets it apart.
Who Are MDBIF's Key Customers?
- Healthcare providers seeking reliable diagnostic tools for mental health disorders.
- Corporations looking for mental well-being programs to support employee health.
- Government and non-profit organizations focused on mental health initiatives.
- Individuals requiring advanced diagnostic solutions for behavioral health issues.
Company Profile
TrivarX Limited operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Mount Lawley, AU. The company is led by CEO Kai Sun. MDBIF has traded publicly since 2017.
How TrivarX Limited Is Valued
TrivarX Limited carries a market capitalization of 873K, placing it in the micro-cap category. Relative to its peer group, MDBIF's quantitative score of 45/100 is below the peer average of 79/100.
ROE -12%Key Financial Metrics
Return on equity for TrivarX Limited stands at -11.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
TrivarX Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.44 places it in the distress zone, a signal of elevated financial risk.
MDBIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative AI-driven diagnostic tools tailored for behavioral health.
- Strong scientific validation enhances product credibility.
- Established presence in both Australian and U.S. markets.
- Dedicated team focused on continuous product development.
Bear Case
- Limited workforce of six employees may restrict growth capacity.
- Dependence on a niche market could limit revenue diversification.
- Recent rebranding may require time to build brand recognition.
- Lack of established partnerships with major healthcare providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MDBIF Latest News
No recent news available for MDBIF.
MDBIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDBIF.
Price Targets
Wall Street price target analysis for MDBIF.
MDBIF MoonshotScore
What does this score mean?
The MoonshotScore rates MDBIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kai Sun
CEO
Kai Sun has a diverse background in healthcare technology and management. With a strong focus on innovation, he has led TrivarX Limited through its rebranding and strategic initiatives aimed at enhancing product offerings and market reach. His experience includes roles in various healthcare organizations where he has successfully implemented technology solutions to improve patient outcomes.
Track Record: Under Kai Sun's leadership, TrivarX has successfully transitioned from Medibio Limited to TrivarX Limited, aligning the company's identity with its innovative approach. He has been instrumental in expanding the company's product portfolio and entering new markets, particularly in the United States.
MDBIF OTC Market Information
TrivarX Limited trades on the OTC Other tier, which includes companies that do not meet the more stringent listing requirements of the NYSE or NASDAQ. This tier provides companies with access to capital markets while maintaining lower disclosure standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may lead to uncertainty regarding the company's performance.
- Lower liquidity can result in higher volatility and difficulty in executing trades.
- Potential regulatory scrutiny due to OTC trading status may impact operations.
- Competition from larger, more established companies may hinder market penetration.
- Review the company's financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Evaluate the management team's experience and track record.
- Investigate any pending regulatory approvals for products.
- Monitor industry trends and growth opportunities.
- Established history since 1987 demonstrates longevity in the market.
- Recent rebranding to TrivarX Limited indicates a strategic focus on innovation.
- Commitment to scientific validation of products enhances credibility.
MDBIF Healthcare Stock FAQ
What does TrivarX Limited do?
TrivarX Limited specializes in developing advanced AI-driven diagnostic tools for behavioral health disorders. The company also offers tailored mental well-being programs for businesses, aiming to improve employee mental health and productivity. By focusing on scientifically validated instruments, TrivarX positions itself as a reliable provider of mental health solutions in both Australia and the United States.
What are the key growth opportunities for MDBIF in healthcare?
TrivarX Limited has several growth opportunities, including expansion into the U.S. market, where the demand for mental health solutions is increasing. The company can leverage its AI-driven diagnostic tools to capture market share and enhance its product offerings. Additionally, the rising awareness of mental health in corporate environments presents a significant opportunity for TrivarX's mental well-being programs.
What are the main risks for MDBIF?
TrivarX Limited faces several risks, including regulatory challenges in obtaining approvals for its diagnostic tools, which could delay product launches. The company also encounters intense competition from established players in the healthcare technology sector, which may hinder its market penetration. Additionally, economic downturns could impact corporate spending on health solutions, affecting revenue growth.
What are the key factors to evaluate for MDBIF?
TrivarX Limited (MDBIF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does MDBIF data refresh on this page?
MDBIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MDBIF's recent stock price performance?
TrivarX Limited (MDBIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative AI-driven diagnostic tools tailored for behavioral health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDBIF overvalued or undervalued right now?
Valuing TrivarX Limited (MDBIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MDBIF?
Before investing in TrivarX Limited (MDBIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company's financial data is limited due to its OTC classification, which may affect the comprehensiveness of the analysis.